hims retatrutide Vial of unapproved peptide had double the strength indicated on label Retatrutide Promises Big Weight Loss,

Some patients continue on low-dose maintenance therapy

In just a single year, the number nearly doubled to 192

Switching from compounded to branded GLP-1 products remains uncommon, with only 2% of patients moving from compounded to branded GLP-1s

Mariette Abrahams, CEO & Founder of Qina, delivered a surprising observation: the biggest and fastest-growing opportunity for the supplement industry lies with the population coming off the drug. She cited high discontinuation rates around 70 percent still taking the drug by month three, dropping to about 40 percent by month six, often due to factors like cost or medical advice creating a vast demographic seeking support to maintain progress and manage lingering effects

We assumed this younger cohort is 80% female, consistent with modeling from the Institute for Clinical and Economic Review (ICER) in its 2022 report estimating an annual VBP of $9,700

J., Cuthbertson, D